Ratings Probi AB

Equities

PROB

SE0001280355

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
270 ^SEK	-0.37%		-9.09%	+33.00%

Jun. 28	Probi AB Announces Products Are Now Also Available in Denmark at Matas	CI
Jun. 27	Probi AB Strengthens the Gut-Brain Offering with New Study in Older Adults	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 202.24 times its estimated earnings per share for the ongoing year.
The company's enterprise value to sales, at 4.26 times its current sales, is high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PROBI AB	+33.00%	294M	C+
ELI LILLY AND COMPANY	+62.66%	841B	C+
NOVO NORDISK A/S	+40.42%	625B	B
JOHNSON & JOHNSON	-4.37%	360B	C+
MERCK & CO., INC.	+17.16%	327B	B-
ABBVIE INC.	+9.87%	300B	C+
ASTRAZENECA PLC	+15.66%	242B	B+
NOVARTIS AG	+17.90%	227B	B-
AMGEN INC.	+14.86%	174B	C+
PFIZER, INC.	+0.45%	162B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes